EXACT Sciences Corporation has announced promising results from the Beta-CORRECT clinical validation study, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study validates the performance of the Oncodetect™ test, a tumor-informed molecular residual disease $(MRD.AU)$ test, in predicting cancer recurrence specifically in stage II-IV colorectal cancer patients. This confirmation of the test's clinical utility supports its role in aiding treatment and surveillance decisions for clinicians and patients. Additionally, Exact Sciences is preparing to launch a next-generation version of the Oncodetect test in 2026, powered by the Broad Institute's MAESTRO technology, which will offer ultra-low limits of detection and the ability to track up to 5,000 patient-specific variants. This advancement aims to enhance sensitivity and expand the clinical utility of cancer detection and monitoring.